US EditionDrugmakers Plan 4% Median Price Increase on 350 Medicines in U.S. for 2026: Report
At least 350 brand-name drugs will see a median U.S. list price increase of about 4% in 2026 despite government pressure to lower costs, data from 3 Axis Advisors shows.
- On January 1, brand-name drugmakers plan to raise U.S. list prices for at least 350 drugs, with a median increase of about 4%, Reuters' exclusive 3 Axis Advisors data show.
- Facing political pressure from the Trump administration, Pfizer Inc. told Reuters its list-price increases remain below inflation and support research and rising business costs for U.S. patients.
- Manufacturers also signalled a small number of cuts, with about nine drugs slated for reductions, including Boehringer Ingelheim's Jardiance cut by more than 40%.
- The U.S. government is negotiating lower Medicare prices for Jardiance and nine other drugs for people 65 and older in 2026, while Reuters reported planned hikes already exceed last year’s 250 drugs.
- The administration has struck pricing deals with 14 manufacturers covering some drugs sold through Medicaid and to cash-paying consumers, despite U.S. patients paying the most for prescription drugs.
21 Articles
21 Articles
U.S. drug prices to rise for 350 medications in 2026
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors. The number of price increases for 2026 is up from the same point last year, when drugmakers unveiled plans for raises on more than 250 drugs.…
Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration pressures them for cuts, according to data provided exclusively by healthcare research firm 3 Axis Advisors.
Coverage Details
Bias Distribution
- 47% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
